Beximco Pharma Regulatory News (BXP)

31 Mar 2006 07:01

Beximco Pharmaceuticals Ltd31 March 2006 BEXIMCO PHARMACEUTICALS LTD. Beximco Pharmaceuticals Ltd introduces drug to combat Bird Flu Beximco Pharmaceuticals Limited (the "Company"), a leading drug manufacturer inBangladesh, has introduced Oseflu to the Bangladesh pharmaceuticals market forthe prevention and treatment of human cases of Avian influenza (H5N1) causingBird flu. The Company believes that the capsule which contains Oseltamivir 75 mg ensuresoutstanding efficacy against pandemic strains of influenza including reducingthe severity and duration of symptoms and the complications arising from anyinfluenza infection and mortality. Due to its safety and effectiveness against pandemic strains of influenza, theWorld Health Organization has recommended Oseltamivir in the event of aninfluenza pandemic. Regarding the launching of the drug a senior Beximco Pharmaceutical officialstated that although they do not believe that bird flu virus has been detectedin Bangladesh, the country, like many others, is potentially at risk as bird fluhas been detected in the neighbouring countries of India and Myanmar. The drug is also effective against both Influenza type A and B and so can beutilised for treatment and prophylaxis of both Influenza type A and B. For more information, please contact: Beximco Pharmaceuticals Limited+880 2 8619 151Nazmul Hassan Libertas Capital Financial Dynamics+44 (0)20 7569 9650 +44 (0)20 7831 3113Aamir Quraishi David Yates About Beximco Pharmaceuticals Limited (LSE: BXP) Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sellsgeneric pharmaceutical formulation products, active pharmaceutical ingredientsand intravenous fluids. The Company also undertakes contract manufacturing forGlaxoSmithKline and is about to commence manufacturing for Novartis. The Companyoperates from a 20 acre site in Dhaka and currently employs over 1800 staff. The Company's products are sold to retail outlets, medical institutions andother pharmaceutical manufacturers in Bangladesh, in regional markets such asPakistan, Nepal and Myanmar and in other markets overseas, principally in EastAfrica (including Kenya) and South East Asia (including Singapore). This information is provided by RNS The company news service from the London Stock Exchange